Meeting Announcement

Article

AACR Colorectal Cancer Conference to Focus on Screening, New Treatments

AACR Colorectal Cancer Conference to Focus on Screening, New Treatments

• Press conference held on Thursday, Oct. 28 at 1:00 p.m. ET at the Loews Hotel.
• New DNA methylation test may change screening landscape.
• Emerging targeted treatments show promise in hard to treat cases.

PHILADELPHIA - The American Association for Cancer Research will hosts its first special conference on Colorectal Cancer: Biology to Therapy from Oct. 27-30, 2010, at the Loews Hotel, Philadelphia.

Colorectal cancer is the third leading cause of cancer in men and women. While screening has brought mortality rates down, much work remains to be done.

“Colorectal cancer is still one of the deadliest cancers, and our current screening methods are not yet always efficient or complete,” said Anil Rustgi, M.D., chief of gastroenterology, T. Grier Miller Professor of Medicine and Genetics, and American Cancer Society Professor at the University of Pennsylvania School of Medicine and a program chairperson of the AACR special conference.

Rustgi will host a press conference on Thursday, Oct. 28 at 1:00 p.m. ET in the Adams Room on the third floor of the Loews Hotel in Philadelphia. The press conference will feature the following new research:

• Telomere Length Affects Colorectal Cancer Risk
• New Colorectal Screening Test Measures DNA Methylation
• FAK Inhibitor Effectively Blocked Colon Cancer Cell Growth and Viability
• Jekyll-Hyde MicroRNA Binding Variant Linked to Improved Outcome in Early-stage Colorectal Cancer

Reporters who cannot attend in person can participate using the following information:

Dial-in (U.S. and Canada): (888) 282-7404
Dial-in (International): (706) 679-5207
Access Code: 18304706

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content